- $24.42m
- $16.00m
- $3.02m
Brief: TherapeuticsMD Completes Transaction To License Its Products To Mayne Pharma
U.S. STOCKS ON THE MOVE-Pot stocks, Nymox, Zynerba
U.S. STOCKS ON THE MOVE-TFF Pharma, BioRestorative,
U.S. STOCKS ON THE MOVE-Energy firms, Nkarta, Domino's Pizza
U.S. STOCKS ON THE MOVE-Casino operators, Miners, Tesla
TherapeuticsMD rises on license deal to flip into a royalty company
Brief: Therapeuticsmd Announces Definitive Agreements To License Its Products To Mayne Pharma
TherapeuticsMD falls as Q3 revenue misses estimate
TherapeuticsMD Inc reports results for the quarter ended in September - Earnings Summary
Brief: TherapeuticsMD Announces Third Quarter 2022 Financial Results
TherapeuticsMD Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Therapeuticsmd Announces Additional $7 Mln Private Placement
Brief: Therapeuticsmd Announces $7 Million Private Placement
Chief Executive Officers
U.S. STOCKS ON THE MOVE-Unity Software, Cardinal Health, Tesla
U.S. STOCKS ON THE MOVE-AEye, Team, Moderna, Snap
TherapeuticsMD Inc reports results for the quarter ended in June - Earnings Summary
TherapeuticsMD jumps after swinging to profit
Brief: Therapeuticsmd Inc Reports Q2 Earnings Per Share Of $12.39